May Daher

Physician scientist at MD Anderson Cancer Center with focus on cellular therapy, gene editing and immunometabolism to treat cancer patients. Tweets are my own.

[May Daher @may_daher]

@jccarnevale @carnevale_lab @GladstoneInst @UCSF @Nature Congratulations Julia, beautiful work! Hope our collaboration will lead to important translational work and benefit patients 🙏

[Katy Rezvani, M.D., Ph.D @lab_rezvani]

The future of medicine will be built at the intersection of engineering, biology, medicine, and AI. Please join us at the inaugural International Society for Engineering Health (ISEH) Summit on Engineering the Elimination of Diseases (Sept. 10–11, Houston), bringing together an outstanding lineup including Phillip Sharp, Francis Collins, David Liu, Huda Zoghbi, Walter Koroshetz, and many more to explore bold new approaches to eliminating disease.

Learn more: https://t.co/gTMuU3FvtB

#ISEH #EngineeringHealth #Bioengineering #CellTherapy #Innovation

[Yan Leyfman, MD @YLeyfman]

Are CAR-NK cells the next evolution of cellular immunotherapy?

While CAR T-cell therapy has transformed the treatment of hematologic malignancies, CAR-natural killer (CAR-NK) cells are emerging as a promising next-generation platform with several potential advantages.

Unlike CAR T cells, CAR-NK cells offer:
🔹 A favorable safety profile with lower rates of severe CRS and neurotoxicity
🔹 Off-the-shelf, allogeneic manufacturing that may improve access and scalability
🔹 Innate anti-tumor activity without prior antigen sensitization

Early clinical trials have demonstrated encouraging responses in hematologic malignancies with minimal severe toxicities.

Challenges remain, including limited in vivo persistence, metabolic constraints, and tumor-induced NK cell exhaustion. However, advances in genetic engineering, cytokine support, and metabolic reprogramming are driving the development of more durable and potent CAR-NK therapies.

As the field continues to evolve, CAR-NK cells have the potential to complement—or in some settings, even expand upon—the success of CAR T-cell therapy, bringing safer and more accessible cellular immunotherapies to patients with blood cancers.

Thank you to Dr Daher & team for a compelling review.

#CARNK #CART #CellTherapy #Hematology #Immunotherapy #Oncology #CancerResearch @may_daher

https://t.co/WhkQ8dIcmh

[May Daher @may_daher]

@YLeyfman Thank you Yan for highlighting our review! Credit goes to the talented Dr.Gohar Manzar and the whole team.

[May Daher @may_daher]

@RuellaLab @MarcoRuella @BloodCancerUtd @PennMedicine Congrats Marco!! Yay! You did it!

[May Daher @may_daher]

@UTMDAnderson Congratulations @ACKoongMDPhD! Excited for what’s ahead! @MDAndersonnews

[May Daher @may_daher]

@AbdelWahablab @ASH_hematology @BloodCancerUtd @theNCI Amazing work! Love the idea. Congratulations and looking forward to the clinical translation!

[May Daher @may_daher]

@DelgoffeLab @Nature Congratulations @DelgoffeLab and team! Super cool science! Love the story and the clinical implications to cell therapy!!

[May Daher @may_daher]

@IamLinghua @UTMDAnderson Congratlations Linghua! Excited for you and your team and looking forward to fruitful collaborations!

[Rizwan Romee @romeerizwan]

Exciting paper showing safety and promising efficacy (69% response rate) using IL-15 secreting CD19 CAR NK cells in advanced lymphoma. Their extended 25 day culture (vs 14d) using their prop freezing may have negatively impacted in vivo persistence. https://t.co/uDFcGWAV2F

[May Daher @may_daher]

Impressive data and translational pipeline out of the Cell Therapy Insitute @UTMDAnderson congratulations @lab_rezvani and the whole team. #NK #CARNK #celltherapy #AACR26

[UT MD Anderson @UTMDAnderson]

At #AACR26, our Dr. Katy Rezvani presented an overview of the past and the future of next-generation cell therapy trials, including nine upcoming studies in collaboration with researchers across UT MD Anderson. Learn more: https://t.co/3iVOR2PCWJ #EndCancer @lab_rezvani

[May Daher @may_daher]

@YLeyfman Thank you Yan for highlighting our work! We are very excited about the potential of this strategy for the treatment of solid tumors!

[May Daher @may_daher]

It was such an exciting session! I had the privilege of presenting some of the work we are doing in my group at the Cell Therapy Institute of @UTMDAnderson led by my super talented postdoctoral fellows @tiberti_silvia and Madison Moore. The session featured outstanding talks by leaders in the field @DelgoffeLab and Owen Sansom. So glad the #immunometabolism field is blooming. Many exciting developments and promising approaches with translational potential. #AACR26 #NK #metabolism

[UT MD Anderson @UTMDAnderson]

At #AACR26, our Dr. May Daher shared how to improve NK cell metabolic fitness and make them more effective cell therapies. Learn more about her research in the Institute for Cell Therapy Discovery & Innovation: https://t.co/4FC3KKrEP9 @may_daher #EndCancer

[May Daher @may_daher]

Congratulations to @rftbsr9 for delivering an outstanding talk showcasing the power of TCR engineered NK cells in a major session at #AACR26. Packed ballroom, many questions and lots of interest in this platform and the promising clinical impact. @UTMDAnderson #NK #TCR #celltherapy

[May Daher @may_daher]

It was an honor to present our work in this immunometabolism session chaired by @DelgoffeLab loved the wonderful talks by Owen Sasom and @DelgoffeLab such exciting work and so much promise for the field! @UTMDAnderson

[Delgoffe Lab @DelgoffeLab]

This was an incredible Immunometabolism session. I’m honored to chair and very happy that the @AACR continues to value giving immune metabolism a platform at the annual meeting.

[May Daher @may_daher]

Congrats to @sunilacharya13 and @YETHANLI on their fantastic poster presentations! @UTMDAnderson

[UT MD Anderson @UTMDAnderson]

Our researchers have a robust offering of poster presentations at #AACR26. From dissecting the mechanisms of drug resistance, to the application of bioinformatics to cancer biology, there is a wide variety of topics to explore. #EndCancer

[May Daher @may_daher]

@AbdelWahablab @DanielleHammo20 @natgenet @KellyLBolton @WashU @IrenaeusChan @PuZhang09980432 Congratulations! Very elegant work with exciting translational implications!

[May Daher @may_daher]

@DelgoffeLab How creative! 🙃

[May Daher @may_daher]

@obenaufa Congrats Anna! So well deserved!! 🎊🎉🎈

[May Daher @may_daher]

@KlebanoffLab @NatureComms @RockefellerUniv @MSKCancerCenter @parkerici Great work! How interesting!